

## S 298

### Pharmacy Benefit Manager Accountability Study Act of 2021

**Congress:** 117 (2021–2023, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Feb 8, 2021

**Current Status:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

**Latest Action:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Feb 8, 2021)

**Official Text:** <https://www.congress.gov/bill/117th-congress/senate-bill/298>

### Sponsor

**Name:** Sen. Blackburn, Marsha [R-TN]

**Party:** Republican • **State:** TN • **Chamber:** Senate

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Braun, Mike [R-IN]	R · IN		Feb 8, 2021

### Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Feb 9, 2021

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
117 S 4293	Related bill	Dec 14, 2022: Placed on Senate Legislative Calendar under General Orders. Calendar No. 647.
117 HR 1829	Identical bill	Mar 12, 2021: Referred to the Subcommittee on Health.

### Summary (as of Feb 8, 2021)

#### Pharmacy Benefit Manager Accountability Study Act of 2021

This bill requires the Government Accountability Office to report on the role of pharmacy benefit managers in the pharmaceutical supply chain and recommend legislative actions to lower the cost of prescription drugs. The report must address the use of rebates and fees, the average prior authorization approval time, and the use of step therapy within the 10 largest pharmacy benefit managers.

### Actions Timeline

- **Feb 8, 2021:** Introduced in Senate
- **Feb 8, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.